New research suggests GLP-1 drugs like Ozempic, Wegovy, Mounjaro may lower the risk of several obesity-related cancers, even matching surgery in preventive benefits
A US judge earlier barred compounders from making copies of Eli Lilly's Zepbound and Mounjaro
Lilly CEO says if approved, drug could be manufactured and launched at scale globally
With obesity on the rise, Eli Lilly's weight-loss injection triggers a rush of consultations as Indians seek safer, cheaper options to black-market drugs
Kapil Sharma, who is gearing up for the sequel to Kis Kisko Pyaar Karoon, left fans stunned with his dramatic weight loss. Social media is abuzz, calling it the 'best example of hard work'
Co claims that the formulation naturally increases GLP-1 levels and regulates appetite
Mounjaro, Eli Lilly's diabetes and obesity drug, is now available in India at a fraction of its US price. It offers treatment for weight loss and diabetes control, but watch out for the side effects
To put into perspective, the weight-loss market is big and, according to industry estimates, it hit $25 billion in 2024, and is expected to expand to $55 billion by 2033
According to his X post, billionaire Harsh Goenka tried the popular 'weight-loss' drink of warm honey-lemon water but it did not work out as planned
Since Novo's blockbuster Ozempic diabetes treatment was approved in the United States in 2017, regulators have greenlighted 22 medicines containing its main ingredient in Bangladesh, Laos, Russia
The finding effectively bars widespread sales of cheaper copies of the drugs that many patients use, but the FDA said it would not take any action against the compounding pharmacies
Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade
Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication kits at $79 per month
The Danish drugmaker's arch-rival Eli Lilly & Co. has introduced another shot - Zepbound, also known as Mounjaro - that so far has shown even more weight loss than Wegovy
Half of the states without coverage said they are considering adding them or evaluating their coverage, it said
The shortage of all doses of the drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management has been resolved
The Food and Drug Administration has listed an ongoing shortage of Lilly's medicines since December 2022
Eli Lilly's Mounjaro, a blockbuster diabetes medication and a highly popular obesity treatment is still awaiting approval from CDSCO despite a SEC clearance
Indi had the third largest number of people with obesity as of 2022, behind China and the US, according to a study in The Lancet, with numbers surging as junk food consumption becomes more commonplace
As they've grown in popularity, we've also heard more about the potential side effects - from common gastrointestinal discomforts, to more serious mental health concerns